WASHINGTON (dpa-AFX) - ArQule Inc. (ARQL) Monday announced a wider net loss
in the third quarter to $5.82 million or $.08 per share compared to $2.354
million or $0.04 per share last year.
On average, 4 analysts polled by Thomson Reuters...
WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) Thursday said it plans to present
the preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in
intrahepatic cholangiocarcinoma with proprietary fibroblast growth factor
WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) Thursday said its preliminary
clinical data for ARQ 087 demonstrated anti-cancer activity in Intrahepatic
Cholangiocarcinoma, a rare liver cancer with a high mortality rate and limited
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.